KZIA Stock — Kazia Therapeutics Ltd ADR

Kazia Therapeutics Ltd ADR (KZIA)

Updated October 16, 2026.

KZIA is a Stock. Its deepest 1-year drawdown was 68.2%.

Kazia Therapeutics is an oncology-focused biotechnology company based in Australia developing small-molecule cancer therapies, with its lead candidate paxalisib in Phase II/III trials for glioblastoma and other brain tumors, and a secondary program in early-stage development for solid tumors. The company does not currently distribute dividends. This security appeals to investors seeking exposure to early-stage oncology drug development with high risk and long-term growth potential rather than current income.

KZIA performance

Returns are updating. KZIA's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 68.2%.

KZIA key facts

Asset type

Stock

Asset class

Equity

Inception date

01/06/1999

Distribution frequency

None

Last close

$7.25 (as of 2026-10-16)

Market cap

$112,729,366

Average volume

273171.0

Last known dates

ex 01/28/2013; payment 07/14/2017

Date quality

Unmatched ex / payment pair — not a live schedule

Beta

2.271

Payout ratio

0.0%

Forward P/E

12.8205

EPS

$-6.85

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

KZIA risks and drawbacks

The deepest 1-year drawdown on record here is 68.2%.

Who may consider KZIA — and who may not

It is a weaker fit for investors who need monthly cash flow (KZIA does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on KZIA

• All tickers starting with K

Tagged: Healthcare.

Frequently asked questions